KDM5D and Alzheimer disease: Recent studies showed that epigenetic processes are distorted in AD patients and that the epigenetic control of enhancers may have an important pathogenetic role [46–48]. Of note is also here that LOY leads to complete inactivation of KDM5D and UTY/KDM6C genes, which are histone demethylases and are located on the male-specific part of chromosome Y. It has been shown that reduced expression of KDM5D results in higher H3K4me3 levels at the target gene promoter [49].